IMPACT OF THE COVID-19 PANDEMIC ON THE ONCOLOGICAL PRACTICE
https://doi.org/10.21294/1814-4861-2020-19-3-5-22
Abstract
Detailed, systematic review of the world literature data, including all aspects that reflect the impact of the COVID-19 pandemic on the oncological practice was conducted. The information sources were taken from Pubmed, MedLine, Scopus, Web of Science, and RSCI systems. The data from retrospective and prospective clinical trials have been analyzed. This review presents current data on the impact of COVID-19 on cancer patients, mortality and prognosis of cancer patients infected with COVID-19, treatment options for COVID-19, as well as the case report of the cancer patient with rare atypical COVID-19 course of disease. To date, the groups of increased risk of being infected with a new coronavirus have been identified. These groups include cancer patients. Despite the pandemic, treatment of cancer patients must be continued, since the presence of a tumor process does not allow the therapy to be delayed. The world cancer community is actively continuing to develop recommendations for optimal management of cancer patients in the context of the pandemic. The most relevant of them are described in this article.
Keywords
About the Authors
A. D. Kaprin
National Medical Research Center of Radiology of Ministry of Health of Russia;
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, DSc, Professor, Member of the Russian Academy of Sciences, Chief Oncologist of Ministry of Health of Russia; General Director of National Medical Research Center of Radiology of Ministry of Health of Russia; Director of P.A. Hertsen Moscow Oncology Research Center,
3, 2nd Botkin Ave., 125284, Moscow
E. V. Gameeva
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, PhD, Deputy Director,
3, 2nd Botkin Ave., 125284, Moscow
A. A. Polyakov
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Clinical Resident,
3, 2nd Botkin Ave., 125284, Moscow
A. L. Kornietskaya
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Department of Chemotherapy,
3, 2nd Botkin Ave., 125284, Moscow
N. A. Rubtsova
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, DSc, Head of Radiology Department,
3, 2nd Botkin Ave., 125284, Moscow
A. A. Fedenko
P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, DSc, Head of the Department of Drug Treatment of Tumors,
3, 2nd Botkin Ave., 125284, Moscow
References
1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S.; China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20. doi: 10.1056/NEJMoa2002032.
2. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26; 382(13): 1199–1207. doi: 10.1056/NEJMoa2001316.
3. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395(10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7.
4. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5; 382(10): 929–936. doi: 10.1056/NEJMoa2001191.
5. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5.
6. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–9. doi: 10.1001/jama.2020.1585.
7. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M., Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15; 395(10223): 514–523. doi: 10.1016/S0140-6736(20)30154-9.
8. Hoehl S., Rabenau H., Berger A., Kortenbusch M., Cinatl J., Bojkova D., Behrens P., Böddinghaus B., Götsch U., Naujoks F., Neumann P., Schork J., Tiarks-Jungk P., Walczok A., Eickmann M., Vehreschild M.J.G.T., Kann G., Wolf T., Gottschalk R., Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020 Mar 26; 382(13): 1278–1280. doi: 10.1056/NEJMc2001899.
9. Wang H., Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020 Apr; 21(4): e181. doi: 10.1016/S1470-2045(20)30149-2.
10. You B., Ravaud A., Canivet A., Ganem G., Giraud P., Guimbaud R., Kaluzinski L., Krakowski I., Mayeur D., Grellety T., Lotz J.P. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020; 21(5): 619–21. doi: 10.1016/S1470-2045(20)30204-7.
11. Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar; 21(3): 335–337. doi: 10.1016/S1470-2045(20)30096-6.
12. Burki T.K. Cancer care in the time of COVID-19. Lancet Oncol. 2020 May; 21(5): 628. doi: 10.1016/S1470-2045 (20)30201-1.
13. Burki T.K. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020 May; 21(5): 629–630. doi: 10.1016/S1470-2045(20)30217-5.
14. Wang Z., Wang J., He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncol. 2020; 6(5): 631632. doi: 10.1001/jamaoncol.2020.1198.
15. ESMO. Cancer patient management during the COVID-19 pandemic [Internet]. URL: https://www.esmo.org/guidelines/cancer-patientmanagement-during-the-COVID-19-pandemic?hit=ehp&page=1 (cited 01.04.2020).
16. Miyashita H., Mikami T., Chopra N., Yamada T., Chernyavsky S., Rizk D., Cruz C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020 Apr 21: S09237534(20)39303-0. doi: 10.1016/j.annonc.2020.04.006.
17. Temporary methodological recommendations: prevention, diagnosis and treatment of new coronaviral infection (COVID-19) [Internet]. URL: https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (cited 01.04.2020). (in Russian).
18. I of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. URL: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(COVID-19) (cited 01.04.2020).
19. Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., Pradhan K., Thota R., Reissman S., Sparano J.A., Gartrell B.A., Smith R.V., Ohri N., Garg M., Racine A.D., Kalnicki S., Perez-Soler R., Halmos B., Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 May 1: CD-20-0516. doi: 10.1158/2159-8290.CD-20-0516.
20. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar; 30(3): 269–271. doi: 10.1038/s41422-020-0282-0.
21. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., Cooley L.A., Dean N.C., Fine M.J., Flanders S.A., Griffin M.R., Metersky M.L., Musher D.M., Restrepo M.I., Whitney C.G. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1; 200(7): e45e67. doi: 10.1164/rccm.201908-1581ST.
22. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020; 395(10223): 473–475. doi: 10.1016/S0140-6736(20)30317-2.
23. Poddubnaya I.V., Sychev D.A. Features of managing of oncological patients during a pandemic of coronavirus infection COVID-19. [Internet]. URL: https://rosoncoweb.ru/news/COVID-19/2020/04/07-2/module.pdf (дата обращения: 01.04.2020). (in Russian).
24. Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., Ng Y.Y., Lo J ., Chan J., Tam A.R., Shum H.P., Chan V., Wu A.K., Sin K.M., Leung W.S., Law W.L., Lung D.C., Sin S., Yeung P., Yip C.C., Zhang R.R., Fung A.Y., Yan E.Y., Leung K.H., Ip J.D., Chu A.W., Chan W.M., Ng A.C., Lee R., Fung K., Yeung A., Wu T.C., Chan J.W., Yan W.W., Chan W.M., Chan J.F., Lie A.K., Tsang O.T., Cheng V.C., Que T.L., Lau C.S., Chan K.H., To K.K., Yuen K.Y. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30; 395(10238): 1695–1704. doi: 10.1016/S0140-6736(20)31042-4.
25. COVID-19: Elective Case Triage Guidelines for Surgical Care. American College of Surgeons. March 24, 2020. https://www.facs.org/COVID-19/clinical-guidance/elective-case/.
26. Mayor S. COVID-19: impact on cancer workforce and delivery of care. Lancet Oncol. 2020 May; 21(5): 633. doi: 10.1016/S1470- 2045(20)30240-0.
27. Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020 Mar 24; 22: 55–68. doi: 10.1016/j.ctro.2020.03.009.
28. Prevention, diagnostics and treatment of new coronavirus infection (COVID-19) in oncologic patients [Internet]. URL: https://oncology-association.ru/files/pdf/2020/COVID.pdf (cited: 01.04.2020). (in Russian).
29. ESMO management and treatment adapted recommendations in the COVID-19 era: primary brain tumours [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID19-pandemic/primary-brain-tumours-in-the-COVID-19-era (cited: 01.04.2020).
30. ESMO management and treatment adapted recommendations in the COVID-19 era: diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphomain-the-COVID-19-era (cited: 01.04.2020).
31. ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-COVID-19-era (cited: 01.04.2020).
32. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/breast-cancer-in-the-COVID-19-era (cited: 01.04.2020).
33. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gastrointestinal-cancers-colorectal-cancer-crc-in-the-COVID-19-era (cited: 01.04.2020).
34. ESMO management and treatment adapted recommendations in the COVID-19 era: renal cell cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/genitourinary-cancers-renal-cell-cancer-in-the-COVID-19-era (cited: 01.04.2020).
35. ESMO management and treatment adapted recommendations in the COVID-19 era: prostate cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19- pandemic/genitourinary-cancers-prostate-cancer-in-the-COVID-19-era (cited: 01.04.2020).
36. ESMO management and treatment adapted recommendations in the COVID-19 era: epithelial ovarian cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-theCOVID-19-era (cited: 01.04.2020).
37. ESMO management and treatment adapted recommendations in the COVID-19 era: melanoma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/melanoma-in-the-COVID-19-era (cited: 01.04.2020).
38. Penel N., Bonvalot S., Minard V., Orbach D., Gouin F., Corradini N., Brahmi M., Marec-Bérard P., Briand S., Gaspar N., Llacer C., Carrère S., Dufresne A., Le Cesne A., Blay J.Y. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann Oncol. 2020 Apr 9; 31(7): 965–966. doi: 10.1016/j.annonc.2020.03.308.
39. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020 Apr; 12(5): 269–273. doi: 10.2217/imt-2020-0067.
40. Mei H., Dong X., Wang Y., Tang L., Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020 May; 21(5): 634–636. doi: 10.1016/S1470- 2045(20)30238-2.
41. Chief freelance oncologist of the Ministry of Health: cancer does not go to quarantine [Internet]. URL: https://tass.ru/interviews/8391689 (cited 01.04.2020). (in Russian).
42. Gerashchenko Ya.L. Review of clinical guidelines for the management of patients with confirmed coronavirus disease (COVID-19) issued by the American national center for immunization and respiratory diseases (NCIRD). Russian Medical Journal [Internet]. URL: https://www.rmj.ru/articles/infektsiya/obzor-klinicheskikh-rekomendatsiy-povedeniyu-patsientov-s-podtverzhdennoy-koronavirusnoy-boleznyu-COVID19-vypushchennykh-amerikanskim-natsionalnym-tsentrom-immunizatsii-irespiratornykh-zabolevaniy-ncird/ (cited 01.04.2020). (in Russian).
Review
For citations:
Kaprin A.D., Gameeva E.V., Polyakov A.A., Kornietskaya A.L., Rubtsova N.A., Fedenko A.A. IMPACT OF THE COVID-19 PANDEMIC ON THE ONCOLOGICAL PRACTICE. Siberian journal of oncology. 2020;19(3):5-22. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-3-5-22
Views:
4571
Email this article 
